NCT02675049View on ClinicalTrials.gov

Efficacy and Optimal Dose Selection of Intranasal Dexmedetomidine During Breast Lumpectomy Under Local Anaesthesia

PHASE2CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

January 31, 2016

Primary Completion Date

February 29, 2016

Study Completion Date

February 29, 2016

Conditions
Intranasal Dexmedetomidine Breast Cancer Local Anaesthesia
Interventions
DRUG

0.9% saline

0.9% saline intranasally 45 min before surgery using a computer-generated random number table.

DRUG

dexmedetomidine 1µg.kg-1

dexmedetomidine 1µg.kg-1 intranasally 45 min before surgery using a computer-generated random number table.

DRUG

dexmedetomidine 1.5µg.kg-1

Dexmedetomidine 1.5µg.kg-1 intranasally 45 min before surgery using a computer-generated random number table.

DRUG

Dexmedetomidine 2µg.kg-1

dexmedetomidine 2µg.kg-1 intranasally 45 min before surgery using a computer-generated random number table.

All Listed Sponsors
lead

Tianjin Medical University Cancer Institute and Hospital

OTHER

NCT02675049 - Efficacy and Optimal Dose Selection of Intranasal Dexmedetomidine During Breast Lumpectomy Under Local Anaesthesia | Biotech Hunter | Biotech Hunter